Minimizing Cardiotoxicities of Contemporary Breast Cancer Treatments

Dr. Anthony F. Yu and patient

It is critical to balance the expected benefits of cancer treatment with cardiovascular risk and identify strategies to prevent cardiotoxicity and improve outcomes and the long-term quality of life for breast cancer survivors.

In our review paper published recently in the journal Current Treatment Options in Oncology, we provided a comprehensive update on the cardiotoxicities associated with contemporary breast cancer treatment and the latest strategies for their prevention, detection, and management. (1)

Assessing patient- and treatment-specific risk factors with appropriate cardiovascular surveillance is an essential component of cancer care. Our multidisciplinary team of specialists includes clinical cardiologists who specialize in the comprehensive management of co-existing cardiovascular disease and cancer and the cardiotoxic side effects of cancer treatment. They work closely with oncologists and radiologists to design individualized treatment plans for each patient.

Cardiotoxicities Associated with Contemporary Breast Cancer Treatments


These agents may lead to chronic, progressive, dose-dependent cardiomyopathy. Doses used for the treatment of breast cancer are typically lower than the thresholds associated with cardiotoxicity risk as defined by the American Society of Clinical Oncology (ASCO), (2) but about nine to 10 percent of patients still experience a significant decline in left ventricle ejection fraction (LVEF), and about 0.6 to 1.3 percent of patients develop heart failure. (3), (4), (5) Strategies to mitigate these adverse effects include continuous versus bolus administration, using a liposomal formulation of doxorubicin, and administering dexrazoxane, a cardioprotective agent that has been shown to lower the risk of left ventricle (LV) dysfunction by about 65 to 80 percent with no apparent impact on treatment efficacy. (6), (7) Dexrazoxane is currently FDA approved for use in patients with metastatic breast cancer who have received at least 300mg/m2 of doxorubicin and have an ongoing indication for additional anthracycline chemotherapy.

It is critical to balance the expected benefits of cancer treatment with cardiovascular risk and identify strategies to prevent cardiotoxicity and improve outcomes and the long-term quality of life for breast cancer survivors.
Anthony F. Yu
Anthony F. Yu

Targeted Therapies

  • Trastuzumab: Combination treatment of trastuzumab plus chemotherapy for adjuvant treatment has been shown to confer a two times greater risk of late-onset heart failure compared to chemotherapy alone. (8) Other risk factors include older age, concomitant cardiovascular risks, and lower baseline LVEF. (4), (5), (9) Cardiac dysfunction most commonly occurs within two years of starting treatment (4), (10) and necessitates treatment interruption in 15–20 percent of patients. (4), (11) However, partial to complete LVEF recovery occurs in up to 80 percent of patients after six or seven months of treatment interruption, either spontaneously, or with medical treatment (11), (12), (13) and some patients can tolerate “rechallenge”. (11)
  • Other Anti-HER2 agents: Pertuzumab is used in neoadjuvant, adjuvant, and metastatic settings. Long-term follow-up studies show it does not increase the risk of cardiotoxicity beyond the risk associated with trastuzumab plus standard chemotherapy. (14), (15), (16), (17)Ado-trastuzumab emtansine (TDM-1), is used to treat metastatic breast cancer that has progressed after treatment with trastuzumab. (18) Recently, it has shown benefits in patients with residual disease after neoadjuvant taxane and trastuzumab therapy. (18), (19) In a Phase III trial for early breast cancer, there was only one (0.1 percent) cardiac event reported after a median follow-up of 40 months. (19)Lapatinib is used in combination with capecitabine or letrozole to treat patients with progressive metastatic HER2-positive cancer. (20) An analysis of Phase I–III trials of more than 3,600 patients found a 1.6 percent incidence of cardiac events at a mean of 13 weeks with an average LVEF decline of 18.8 percent from baseline and a partial or full recovery by 7.6 weeks in a majority of patients. (21)

Cyclin-Dependent kinase 4/6 Inhibitors

Abemaciclib, palbociclib, and ribociclib are used together with endocrine therapies to treat patients with hormone receptor-positive HER2-negative breast cancer. A meta-analysis of phase II and phase III studies found a 3.5-fold higher risk of venous thromboembolism (VTE). (22) A phase I study of ribociclib found a dose-dependent QTc prolongation starting at 600 mg/day. (23) The product label for ribociclib recommends QTc monitoring at baseline, day 14, the beginning of cycle two (day 28), and after that as necessary, with dose reduction and/or interruption for QTc prolongation. (24)

Endocrine Therapy

Third-generation aromatase inhibitors (AIs) including anastrozole, letrozole, and exemestane are used in long-term adjuvant settings in early disease or as first-line therapy in advanced, hormone-receptor-positive disease. (25) They confer better disease benefits and overall survival compared to tamoxifen but have also demonstrated a 19 percent increased risk of cardiovascular events in a meta-analysis of randomized controlled trials. (26) AIs are associated with unfavorable lipid changes (27), (28) and an increase of up to 13 percent in the incidence of hypertension and significant vascular dysfunction. (29) Tamoxifen has been associated with positive lipid changes but has also demonstrated an almost two-fold greater risk of thrombogenicity, up to a 5 percent rate of VTE. (23), (30)

Radiation-Induced Ischemic Heart Disease

Incident radiation of cardiac tissues can cause damage that manifests as coronary artery disease or cardiomyopathy. (31) Cancer survivors have a two to 5.9 times greater risk of radiation-induced heart disease. (32) Darby et al. found a 7.4 percent increased risk of major coronary events per Gray (Gy) of mean heart dose of radiation therapy, beginning within the first few years of exposure and continuing after 20 years. Patients who received left-sided versus right-sided radiation therapy had a 29 percent and 22 percent higher risk for coronary heart disease and cardiac death, respectively. (33) Contemporary techniques including CT-based simulation, prone imaging, respiratory gating, heart blocks, intensity-modulated radiation therapy, and volumetric modulated arc therapy have substantially reduced the radiation dose to the heart and helped to minimize adverse effects. (34)

Back to top

Strategies to Prevent, Detect, and Manage Cardiotoxicities

Pretreatment Evaluation

Pretreatment evaluation of cardiovascular disease risk is recommended before patients initiate cancer treatment with known cardiotoxic effects. This includes a physical examination, taking a comprehensive health history, and baseline LVEF assessment. Patients with pre-existing cardiovascular disease or its risk factors should be screened and managed throughout treatment according to ASCO guidelines. (2)

Primary Prevention

Results have been modest and mixed for studies that have evaluated the efficacy of various renin-angiotensin system-blocking and beta-blocking agents to prevent LV systolic dysfunction associated with adjuvant anthracycline and/or trastuzumab therapy. (1) In a promising study by Guglin et al. lisinopril and carvedilol demonstrated effectiveness for preventing LVEF decline among patients treated with sequential anthracyclines and trastuzumab. (35) Statins may also be beneficial. A retrospective cohort study found that statin use during anthracycline therapy was associated with a decreased risk of heart failure. (36) The prospective PREVENT Trial, which is examining the prophylactic value of atorvastatin in patients planned to receive adjuvant anthracycline, is ongoing with an estimated primary completion date of May 2020.

Early Detection and Management of Cardiotoxicity

Current recommendations for monitoring treatment-related cardiotoxicities include routine LVEF assessments during and after anthracycline and anti-HER2 therapy, for example, at baseline and every three months during treatment. (37), (38) However, adherence to this schedule is poor at less than 50 percent, despite age or other cardiovascular comorbidities. (39), (40) The value of frequent monitoring among low-risk patients has been questioned, especially among patients who are receiving regimens with low cardiotoxic risks. Results from several small studies suggest that patients with asymptomatic LVEF decline can safely continue anti-HER2 therapy with close monitoring and treatment with cardiac medications. (41), (42)

Global longitudinal strain (GLS) via speckle tracking echocardiography is a sensitive measure of LV systolic function and can detect early signs of cardiotoxicity. (43) A study by Negishi et al. demonstrated that an 11 percent change in GLS from baseline to six months was the strongest predictor of cardiotoxicity among patients treated with trastuzumab. (44) The American Society of Echocardiography guidelines state that a relative decrease in GLS of more than 15 percent is likely to reveal a clinically significant drop in LV function that may warrant intervention. (33) The SUCCOUR trial is an international prospective randomized trial comparing the effectiveness of GLS to ejection-fraction management strategies in 320 patients taking cardiotoxic chemotherapy. (45)

Since there is significant heterogeneity in tolerance to cardiotoxic cancer therapy, genetics may provide new insights. Changes in gene expression in response to therapy (46) and single nucleotide polymorphisms in genes involved with anthracycline metabolism and oxidative stress, such as ABCC2, CYBA, RAC2, ABCV1, and CBR3, have been proposed as biomarkers for identifying patients at high risk for cardiotoxicities associated with anthracyclines. (47), (48), (49) The HER2/neu Pro 1170 Ala polymorphism has been identified as a potential genetic marker for cardiotoxicity associated with trastuzumab. (44), (50), (51), (52)

Exercise and Fitness

The multiple hit of pre-existing cardiovascular disease risk factors, cardiotoxicities associated with treatment, and the weight gain, decreased physical activity, and impaired exercise capacity that commonly occur during treatment, can combine to result in cardiovascular disease. (53) Studies have shown that exercise during and after treatment is safe and may provide cardiovascular benefits. (54), (55), (56), (57) The OptiTrain trial showed that high-intensity interval training during treatment resulted in multiple benefits, including preventing cardiorespiratory fitness decline, reducing cancer-related fatigue, and improving muscle strength. (52) Several prospective studies are ongoing to evaluate the impact of exercise on cancer and cardiovascular outcomes. (58), (59)

Back to top

Advancing Cardio-Oncologic Care

As advances in breast cancer treatment continue to improve survival outcomes, more patients are at risk for developing late adverse cardiovascular effects. Our cardio-oncology clinical research is focused on finding new ways to prevent, detect earlier, and better manage the cardiotoxic side effects of cancer treatment. 

We are conducting a research study to investigate why some patients experience reduced heart function by creating cardiomyocytes derived from the blood of breast cancer patients treated with doxorubicin followed by trastuzumab therapy, or trastuzumab alone. The PREVENT-HF Trial is a Phase IIB study testing whether the drug carvedilol can reduce the risk of heart failure in survivors of childhood cancers who received anthracycline drugs. We are conducting an NCI-funded study to evaluate the cardiac safety of less frequent cardiac monitoring in low risk patients treated with non-anthracycline trastuzumab based regimens. MSK is also participating in the randomized RADCOMP consortium trial comparing 10-year cardiovascular outcomes of patients with non-metastatic breast cancer treated with proton versus photon radiotherapy. 

Dr. Lee Chuy declares no conflict of interest. Dr. Yu has received compensation from Glenmark Pharmaceuticals, Takeda Oncology, Bristol-Myers Squibb, and Bayer for consulting services.

Back to top

  1. Lee Chuy K, Yu AF. Cardiotoxicity of Contemporary Breast Cancer Treatments. Curr Treat Options Oncol. 2019;20(6):51.

  2. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35(8):893–911. 

  3. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–8.

  4. Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(31):3792–9.

  5. Advani PP, Ballman KV, Dockter TJ, et al. Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial. J Clin Oncol. 2016;34(6):581–7.

  6. Marty M, Espie M, Llombart A, et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol. 2006;17(4):614–22.

  7. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15:1318–32.

  8. Banke A, Fosbol EL, Ewertz M, et al. Long-term risk of heart failure in breast cancer patients after adjuvant chemotherapy with or without trastuzumab. JACC Heart Fail. 2019;7(3):217–24.

  9. Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014;3(1):e000472.

  10. Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195–205.

  11. Yu AF, Yadav NU, Lung BY, et al. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Breast Cancer Res Treat. 2015;149(2):489–95.

  12. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–21.

  13. de Azambuja E, Procter MJ, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol. 2014;32(20):2159–65.

  14. von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122–31. 

  15. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–34. 

  16. Gianni L, Pienkowski T, Im Y-H, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791–800. 

  17. Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer. 2018;89:27–35. 

  18. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91. 

  19. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2018;380:617–28. 

  20. Tykerb (lapatinib) [package insert]. GlaxoSmithKline, Research Triangle Park, NC. 2007.

  21. Perez EA, Koehler M, Byrne J, et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83(6):679–86.

  22. Thein KZ, Ball S, Zaw MH, et al. Updated meta-analysis of randomized controlled trials (RCTs) to determine the CDK 4/6 inhibitors associated venous thromboembolism (VTE) risk in hormone receptor-positive breast cancer (BC) patients. Ann Oncol. 2018;29(suppl_8):viii603-viii40.

  23. Infante JR, Cassier PA, Gerecitano JF, et al. A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2016;22(23):5696–705.

  24. Kisqali (ribociclib) [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, NJ. 2017.

  25. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2018;37(5):423–38.

  26. Khosrow-Khavar F, Filion KB, Al-Qurashi S, et al. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2017;28(3):487–96.

  27. Esteva FJ, Hortobagyi GN. Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. Breast. 2006;15:301–12.

  28. Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17):1299–309.

  29. Blaes A, Beckwith H, Florea N, et al. Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study. Breast Cancer Res Treat. 2017;166(2):541–7.

  30. The Arimidex, Tamoxifen, Alone or in Combination Trialists’ Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006;7(8):633–43.

  31. Taunk NK, Haffty BG, Kostis JB, Goyal S. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front Oncol. 2015;5:39.

  32. Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2013;14(8):721–40.

  33. Cheng YJ, Nie XY, Ji CC, et al. Long-term cardiovascular risk after radiotherapy in women with breast cancer. J Am Heart Assoc. 2017;6(5).

  34. van den Bogaard VA, Ta BD, van der Schaaf A, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures. J Clin Oncol. 2017;35(11):1171–8.

  35. Guglin ME. Lisinopril or carvedilol for prevention of trastuzumab induced cardiotoxicity - lisinopril or carvedilol for cardiotoxicity. Presented at American College of Cardiology Annual Scientific Session (ACC 2018); March 11, 2018; Orlando, FL2018.

  36. Seicean S, Seicean A, Plana JC, et al. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012;60(23):2384–90.

  37. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911–39.

  38. Florido R, Smith KL, Cuomo KK, Russell SD. Cardiotoxicity From human epidermal growth factor receptor-2 (HER2) targeted therapies. J Am Heart Assoc. 2017;6(9).

  39. Chavez-MacGregor M, Niu J, Zhang N, et al. Cardiac monitoring during adjuvant trastuzumab-based chemotherapy among older patients with breast cancer. J Clin Oncol. 2015;33(19):2176–83.

  40. Henry ML, Niu J, Zhang N, et al. Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients. JACC Cardiovasc Imaging. 2018;11(8):1084–93.

  41. Lynce F, Barac A, Geng X, et al. SAFE-HEaRt: a pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function. J Clin Oncol. 2018;36(15_suppl):1038.

  42. Hussain Y, Drill E, Dang CT, Liu JE, Steingart RM, Yu AF. Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction. Breast Cancer Res Treat. 2019.

  43. Thavendiranathan P, Poulin F, Lim KD, et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014;63(25 Pt A):2751–68.

  44. Negishi K, Negishi T, Hare JL, et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013;26(5):493–8.

  45. Negishi T, Thavendiranathan P, Negishi K, et al. Rationale and design of the strain surveillance of chemotherapy for improving cardiovascular outcomes: the SUCCOUR trial. JACC Cardiovasc Imaging. 2018;11(8):1098–105.

  46. Todorova VK, Makhoul I, Siegel ER, et al. Biomarkers for presymptomatic doxorubicin-induced cardiotoxicity in breast cancer patients. PLoS One. 2016;11(8):e0160224.

  47. Leong SL, Chaiyakunapruk N, Lee SW. Candidate gene association studies of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis. Sci Rep. 2017;7(1):39.

  48. Hertz DL, Caram MV, Kidwell KM, et al. Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. Pharmacogenomics. 2016;17(3):231–40.

  49. Serie DJ, Crook JE, Necela BM, et al. Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial. Pharmacogenet Genomics. 2017;27(10):378–85.

  50. Boekhout AH, Gietema JA, Milojkovic Kerklaan B, et al. Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. JAMA Oncol. 2016;2(8):1030–7.

  51. Gomez Pena C, Davila-Fajardo CL, Martinez-Gonzalez LJ, et al. Influence of the HER2 Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients: a meta-analysis. Pharmacogenet Genomics. 2015;25(8):388–93.

  52. Stanton SE, Ward MM, Christos P, et al. Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity. BMC Cancer. 2015;15(1).

  53. Jones LW, Haykowsky MJ, Swartz JJ, et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol. 2007;50(15):1435–41.

  54. Yu AF, Jones LW. Breast cancer treatment-associated cardiovascular toxicity and effects of exercise countermeasures. Cardiooncology. 2016;2.

  55. Scott JM, Iyengar NM, Nilsen TS, et al. Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: a randomized controlled trial. Cancer. 2018;124(12):2552–60.

  56. Hornsby WE, Douglas PS, West MJ, et al. Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial. Acta Oncol. 2014;53(1):65–74.

  57. Mijwel S, Backman M, Bolam KA, et al. Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial. Breast Cancer Res Treat. 2018;169(1):93–103.

  58. Pituskin E, Haykowsky M, McNeely M, et al. Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN). BMC Cancer. 2016;16(1):733.

  59. Courneya KS, McNeely ML, Culos-Reed SN, et al. The Alberta moving beyond breast cancer (AMBER) cohort study: recruitment, baseline assessment, and description of the first 500 participants. BMC Cancer. 2016;16:481.